All In Biotech

Drug Trial Radar · NCT02965456

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 820 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

820

Actual

Start

Nov 4, 2015

Primary completion

Feb 23, 2017

Study completion Feb 23, 2017

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Nov 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score \[EGSS\] of 3 \[moderate\] or 4 \[severe\]).

Conditions

  • Acne

Interventions

  • IDP 121 LotionDrug

    IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.

  • IDP-121 Vehicle LotionDrug

    IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12Time frame: Baseline (Day 0), Week 12
  2. Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12Time frame: Baseline, Week 12
  3. Percentage of Participants With Treatment Success at Week 12Time frame: Baseline, Week 12

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Valeant Site 21

    Glendale, Arizona

  • Valeant Site 34

    Rogers, Arkansas

  • Valeant Site 25

    Anaheim, California

  • Valeant Site 18

    Beverly Hills, California

  • Valeant Site 09

    Fremont, California

  • Valeant Site 17

    Murrieta, California

  • Valeant Site 26

    Oxnard, California

  • Valeant Site 22

    Sacramento, California

  • Valeant Site 02

    San Diego, California

  • Valeant Site 04

    San Diego, California

  • Valeant Site 19

    Santa Monica, California

  • Valeant Site 15

    Miami, Florida

  • Valeant Site 11

    Miami, Florida

  • Valeant Site 27

    Pinellas Park, Florida

  • Valeant Site 31

    Sanford, Florida

  • Valeant Site 05

    Tampa, Florida

  • Valeant Site 28

    Marietta, Georgia

  • Valeant Site 16

    Buffalo Grove, Illinois

  • Valeant Site 06

    Indianapolis, Indiana

  • Valeant Site 12

    Overland Park, Kansas

  • Valeant Site 32

    Crowley, Louisiana

  • Valeant Site 30

    Clarkston, Michigan

  • Valeant Site 03

    Detroit, Michigan

  • Valeant Site 20

    Henderson, Nevada

  • Valeant Site 08

    New York, New York

  • Valeant Site 23

    Winston-Salem, North Carolina

  • Valeant Site 29

    Hazleton, Pennsylvania

  • Valeant Site 24

    Johnston, Rhode Island

  • Valeant Site 10

    Austin, Texas

  • Valeant Site 01

    Houston, Texas

  • Valeant Site 33

    Port Arthur, Texas

  • Valeant Site 07

    San Antonio, Texas

  • Valeant Site 13

    San Antonio, Texas

  • Valeant Site 14

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.